Information Provided By:
Fly News Breaks for July 11, 2019
Jul 11, 2019 | 08:38 EDT
B. Riley FBR analyst Harshita Polishetty started Spectrum Pharmaceuticals with a Buy rating and $18 price target. Poziotinib is the company's most exciting drug as it shows blockbuster potential for patients with exon 20 mutations, an area of unmet need, Polishetty tells investors in a research note. The analyst believes the drug has potential to transform the "rapidly changing" non-small cell lung cancer treatment paradigm.
News For SPPI From the Last 2 Days
There are no results for your query SPPI